On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Sutro Biopharma (United States)

InstitutionResearch output, impact & collaborations

Sutro Biopharma (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Sutro Biopharma (United States)?

ScholarIQrecord summary

Sutro Biopharma (United States) is a research organisation in South San Francisco, US. OpenAlex records 145 works and 24,874 citations for it. 115 researchers list it as their most recent affiliation.

How many works does Sutro Biopharma (United States) have?

ScholarIQindexed works

Sutro Biopharma (United States) has 145 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Sutro Biopharma (United States) →

How many citations does Sutro Biopharma (United States) have?

ScholarIQcitation count

Sutro Biopharma (United States) has 24,874 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Sutro Biopharma (United States) →

How many researchers are at Sutro Biopharma (United States)?

ScholarIQresearcher count

Sutro Biopharma (United States) has 115 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Sutro Biopharma (United States)?

ScholarIQavg h-index

Sutro Biopharma (United States) has an average h-index of 57 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Sutro Biopharma (United States)?

ScholarIQror

The ROR for Sutro Biopharma (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Sutro Biopharma (United States)?

ScholarIQopenalex

The OpenAlex for Sutro Biopharma (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Sutro Biopharma (United States)?

ScholarIQtop researchers by citations

Hans‐Peter Gerber · HER2/EGFR in Cancer Research

240 works28,119 citations

Young Joo Park · Legal and Regulatory Analysis

1,417 works20,010 citations

Mark Armanini · Nerve injury and regeneration

77 works17,330 citations

What are the most-cited papers on Sutro Biopharma (United States)?

ScholarIQmost cited works

Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers

Seong‐Keun Yoo, Seungbok Lee, Su‐jin Kim, Hyeon‐Gun Jee, Byoung-Ae Kim, Hyesun Cho, Young Shin Song, Sun Wook Cho, Jae‐Kyung Won, Jong-Yeon Shin, Do Joon Park, Jong‐Il Kim, Kyu Eun Lee, Young Joo Park, Jeong‐Sun Seo

PLoS Genetics. 2016352 CitationsOPEN ACCESS

Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

Frank Loganzo, Xingzhi Tan, Matthew Sung, Guixian Jin, Jeremy S. Myers, Eugene Melamud, Fang Wang, Veronica Diesl, Maximillian T. Follettie, Sylvia Musto, My‐Hanh Lam, William T. Hu, Manoj B. Charati, Kiran Khandke, Kenny Sung Kyoo Kim, Mike Cinque, Judy Lucas, Edmund I. Graziani, Andreas Maderna, Christopher J. O’Donnell, Kim Arndt, Hans‐Peter Gerber

Molecular Cancer Therapeutics. 2015274 Citations

Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer

Seong‐Keun Yoo, Young Shin Song, Eun Kyung Lee, Jinha Hwang, Hwan Hee Kim, Gyeongseo Jung, Young A Kim, Su‐jin Kim, Sun Wook Cho, Jae‐Kyung Won, Eun‐Jae Chung, Jong-Yeon Shin, Kyu Eun Lee, Jong‐Il Kim, Young Joo Park, Jeong‐Sun Seo

Nature Communications. 2019271 CitationsOPEN ACCESS

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients

Young Shin Song, Jung‐Ah Lim, Hoon Choi, Jae‐Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park, Jeong‐Sun Seo

Cancer. 2016190 CitationsOPEN ACCESS

How much of the research on Sutro Biopharma (United States) is open access?

ScholarIQopen access share

75%OPEN ACCESS

Gold

50%

Green

Hybrid

Bronze

25%

Closed

25%